<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756873</url>
  </required_header>
  <id_info>
    <org_study_id>Etoric-TE-1</org_study_id>
    <nct_id>NCT00756873</nct_id>
  </id_info>
  <brief_title>Etoricoxib in Ear Nose Throat Surgery</brief_title>
  <official_title>Analgesic Efficacy and Safety of Etoricoxib in Ear Nose Throat Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the analgesic efficacy of etoricoxib (90 mg or 120 mg qd.&#xD;
      perioperatively) for post-operative pain relief.&#xD;
&#xD;
      The primary endpoint is as follows:&#xD;
&#xD;
        -  does preoperative etoricoxib reduce the post-operative opioid utilization in patients&#xD;
           undergoing elective tonsillectomy under general anaesthesia (i.e. the post-operative&#xD;
           opioid-sparing effect of etoricoxib in humans).&#xD;
&#xD;
      The secondary endpoints are as follows:&#xD;
&#xD;
        -  does the etoricoxib medication have an impact on PONV or activities of daily&#xD;
&#xD;
        -  does the etoricoxib medication influence the blood loss during surgery or the incidence&#xD;
           of postoperative bleeding&#xD;
&#xD;
        -  does the etoricoxib medication influence the operation time. In addition, adverse&#xD;
           effects of etoricoxib will be documented.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On day of surgery (day 0) the patients will be randomly assigned to one of the three groups&#xD;
      using a sealed envelope method. The etoricoxib 90 mg group receives etoricoxib (Arcoxia®,&#xD;
      Merck Sharp &amp; Dohme GmbH, Haar, Germany) 90 mg orally, the etoricoxib 120 mg group receives&#xD;
      etoricoxib 120 mg orally and the control group receives a placebo tablet orally 1 h before&#xD;
      surgery (day 0). All patients receive a standard general anesthesia with intravenous propofol&#xD;
      (2-3 mg/kg), fentanyl (2 µg/kg) and mivacurium (0.2 mg/kg) for induction. Patients are&#xD;
      ventilated via a tracheal tube, anesthesia being maintained with sevoflurane (0.8 - 1.5%&#xD;
      end-tidal concentration). If mean arterial blood pressure or heart rate increase to more than&#xD;
      25% above the pre-operative baseline value despite an end-tidal concentration of 1.5%&#xD;
      sevoflurane, an intravenous bolus of fentanyl 0.05 mg will be administered. Monitoring&#xD;
      includes electrocardiogram (ECG), non-invasive arterial blood pressure, pulse oximetry,&#xD;
      end-tidal CO2 and end-tidal sevoflurane. On days 1 to 3 patients will receive etoricoxib (90&#xD;
      mg or 120 mg qd.) or placebo. After discharge on day 3, patients will receive etoricoxib (90&#xD;
      mg or 120 mg qd.) or placebo until cessation of pain during activity (swallowing). According&#xD;
      to the current label for Arcoxia® 120 mg in Germany, patients taking etoricoxib 120 mg will&#xD;
      switch to etoricoxib 90 mg on day 8. Rescue medication will be piritramid i.v. (day 0),&#xD;
      oxycodone p.o. (day 1-2) and paracetamol p.o. (day 3-14).&#xD;
&#xD;
      Day -7 to -1: Inclusion/exclusion criteria, medical history, concomitant medications,&#xD;
      laboratory, serum pregnancy test, informed consent Day 0: Study medication 1 h before&#xD;
      surgery, intra-operative blood loss, pain score, opioid utilization, PONV score and&#xD;
      anti-emetic medication Day 1: pain score, opioid utilization, PONV score, anti-emetic&#xD;
      medication, bleeding Day 2: pain score, opioid utilization, PONV score, anti-emetic&#xD;
      medication, bleeding Day 3: pain score, opioid utilization, PONV score, anti-emetic&#xD;
      medication, bleeding Day 7: pain score, paracetamol utilization, bleeding Day 14: first day&#xD;
      with no pain, last study medication, paracetamol utilization, bleeding&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative opioid-sparing effect of etoricoxib in humans undergoing elective tonsillectomy</measure>
    <time_frame>Day 0-3 after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of etoricoxib medication on PONV or activities of daily or the incidence of postoperative bleeding</measure>
    <time_frame>Day 0-14</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Tonsillectomy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etoricoxib 90 mg qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etoricoxib 120 mg qd. (day 0-7) Etoricoxib 90 mg qd. (day 8-14)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of placebo</intervention_name>
    <description>Placebo qd orally day 0-14</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of etoricoxib</intervention_name>
    <description>Etoricoxib 90 mg qd orally day 0-14</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of etoricoxib</intervention_name>
    <description>Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female patients&#xD;
&#xD;
          -  18 years of age&#xD;
&#xD;
          -  female patients not pregnant/non-lactating&#xD;
&#xD;
          -  indication for elective tonsillectomy&#xD;
&#xD;
          -  written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  etoricoxib, other analgesic or anti-emetic medication within 10 half-lives&#xD;
&#xD;
          -  evidence for active peptic ulceration&#xD;
&#xD;
          -  history of gastrointestinal bleeding&#xD;
&#xD;
          -  evidence of hepatic, renal or hematopoietic disorders&#xD;
&#xD;
          -  heart failure (NYHA II-IV)&#xD;
&#xD;
          -  uncontrolled arterial hypertension&#xD;
&#xD;
          -  clinical evidence of arterial occlusive disease&#xD;
&#xD;
          -  coronary heart disease or cerebrovascular disease&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  hypersensitivity to analgetics, antipyretics, NSAIDs or antiemetics&#xD;
&#xD;
          -  evidence for noncompliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Bucher, MD, PhD</last_name>
    <phone>xx49-941-944-</phone>
    <phone_ext>0</phone_ext>
    <email>michael.bucher@klinik.uni-regensburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universtiy Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Bucher, MD, PhD</last_name>
      <phone>xx49-941-944-</phone>
      <phone_ext>0</phone_ext>
      <email>michael.bucher@klinik.uni.regensburg.de</email>
    </contact>
    <investigator>
      <last_name>Michael Bucher, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Kühnel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weiden Clinic</name>
      <address>
        <city>Weiden i.d. OPf.</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jürgen Altmeppen, MD</last_name>
      <phone>xx49-9 61-303-</phone>
      <phone_ext>32 02</phone_ext>
      <email>anaesthesie@klinikum-weiden.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Altmeppen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <last_update_submitted>September 19, 2008</last_update_submitted>
  <last_update_submitted_qc>September 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Michael Bucher, MD, PhD</name_title>
    <organization>University Hospital Regensburg</organization>
  </responsible_party>
  <keyword>Elective tonsillectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

